March 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
Tailoring Chemotherapy for Low-Grade Gliomas
December 15th 2014The recent evidence that incorporation of chemotherapeutic interventions can result in relatively long survival times for patients with low-grade glioma highlights the need to also preserve neurocognitive function and health-related quality of life in these patients.
Management of Breast Cancer Brain Metastases Is Moving Forward, but New Options Are Still Needed
July 15th 2014Prevention of CNS seeding early in the metastatic disease course using drugs with both intra- and extracranial activity will be crucial to improving outcomes in patients with breast cancer brain metastases.
Updates on the Management of Breast Cancer Brain Metastases
July 15th 2014In this overview, we will review recent developments in the management of breast cancer brain metastases and current prospective trials of systemic therapies specifically for patients with breast cancer brain metastases, with a focus on novel pathway-specific therapies.
High-Dose Chemo Before RT Results in High Survival in Pediatric Brain Tumors
June 10th 2014High-dose chemotherapy plus conventional radiotherapy resulted in a high 3-year overall survival in children and adolescents with newly diagnosed medulloblastoma and supratentorial primitive neuroectodermal tumor.
Molecular Classification of Diffuse Gliomas
June 15th 2013Significant progress has been made in defining molecular signatures in diffuse gliomas. The clinically significant genetic alterations identified to date probably represent the tip of the iceberg, since new, potentially significant biomarkers are continuously described.
Tailored Therapy in Diffuse Gliomas: Using Molecular Classifiers to Optimize Clinical Management
June 15th 2013We review the current data regarding the prognostic and predictive value of IDH mutation and 1p/19q codeletion in gliomas. We also discuss possible management algorithms using these biomarkers to tailor surgical and adjuvant therapy for specific diffuse gliomas.
Oligodendrogliomas: Questions Answered, Answers Questioned
April 15th 2013In light of the high bar that must be met for results to be truly practice-changing, and of the long period of time before survival results are mature in an indolent disease, the primary endpoint for clinical trials in anaplastic oligodendroglial tumors needs rethinking.